BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chu X, Korzekwa K, Elsby R, Fenner K, Galetin A, Lai Y, Matsson P, Moss A, Nagar S, Rosania GR, Bai JP, Polli JW, Sugiyama Y, Brouwer KL; International Transporter Consortium. Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver. Clin Pharmacol Ther 2013;94:126-41. [PMID: 23588320 DOI: 10.1038/clpt.2013.78] [Cited by in Crossref: 172] [Cited by in F6Publishing: 162] [Article Influence: 19.1] [Reference Citation Analysis]
Number Citing Articles
1 Tournier N, Stieger B, Langer O. Imaging techniques to study drug transporter function in vivo. Pharmacol Ther 2018;189:104-22. [PMID: 29684469 DOI: 10.1016/j.pharmthera.2018.04.006] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 11.3] [Reference Citation Analysis]
2 Sun Y, Chothe PP, Sager JE, Tsao H, Moore A, Laitinen L, Hariparsad N. Quantitative Prediction of CYP3A4 Induction: Impact of Measured, Free, and Intracellular Perpetrator Concentrations from Human Hepatocyte Induction Studies on Drug-Drug Interaction Predictions. Drug Metab Dispos 2017;45:692-705. [DOI: 10.1124/dmd.117.075481] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
3 Mandal S, Prathipati PK, Sunagawa SW, Destache CJ. A Concept Evaluation Study of a New Combination Bictegravir plus Tenofovir Alafenamide Nanoformulation with Prolonged Sustained-Drug-Release Potency for HIV-1 Preexposure Prophylaxis. Antimicrob Agents Chemother 2021;65:e02320-20. [PMID: 33526487 DOI: 10.1128/AAC.02320-20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Roe AL, Paine MF, Gurley BJ, Brouwer KR, Jordan S, Griffiths JC. Assessing Natural Product-Drug Interactions: An End-to-End Safety Framework. Regul Toxicol Pharmacol 2016;76:1-6. [PMID: 26776752 DOI: 10.1016/j.yrtph.2016.01.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
5 Pastor CM. Isolated Perfused Rat Livers to Quantify the Pharmacokinetics and Concentrations of Gd-BOPTA. Contrast Media Mol Imaging 2018;2018:3839108. [PMID: 30116162 DOI: 10.1155/2018/3839108] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
6 Sager JE, Yu J, Ragueneau-Majlessi I, Isoherranen N. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification. Drug Metab Dispos 2015;43:1823-37. [PMID: 26296709 DOI: 10.1124/dmd.115.065920] [Cited by in Crossref: 206] [Cited by in F6Publishing: 172] [Article Influence: 29.4] [Reference Citation Analysis]
7 Zhuang X, Lu C. PBPK modeling and simulation in drug research and development. Acta Pharm Sin B 2016;6:430-40. [PMID: 27909650 DOI: 10.1016/j.apsb.2016.04.004] [Cited by in Crossref: 159] [Cited by in F6Publishing: 134] [Article Influence: 26.5] [Reference Citation Analysis]
8 Volpe DA, Qosa H. Challenges with the precise prediction of ABC-transporter interactions for improved drug discovery. Expert Opin Drug Discov 2018;13:697-707. [PMID: 29943645 DOI: 10.1080/17460441.2018.1493454] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Francis L, Harrell A, Hallifax D, Galetin A. Utilising Magnetically Isolated Lysosomes for Direct Quantification of Intralysosomal Drug Concentrations by LC-MS/MS Analysis: An Investigatory Study With Imipramine. J Pharm Sci 2020;109:2891-901. [PMID: 32504630 DOI: 10.1016/j.xphs.2020.05.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Nicolai J, De Bruyn T, Thevelin L, Augustijns P, Annaert P. Transport-Metabolism Interplay of Atazanavir in Rat Hepatocytes. Drug Metabolism and Disposition 2016;44:389-97. [DOI: 10.1124/dmd.115.068114] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
11 Iwasaki S, Kosugi Y, Zhu AZX, Nakagawa S, Sano N, Funami M, Kosaka M, Furuta A, Hirabayashi H, Amano N. Application of unbound liver-to-plasma concentration ratio to quantitative projection of cytochrome P450-mediated drug-drug interactions using physiologically based pharmacokinetic modelling approach. Xenobiotica 2019;49:1251-9. [PMID: 30516093 DOI: 10.1080/00498254.2018.1547461] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
12 Maiuri AR, Wassink B, Turkus JD, Breier AB, Lansdell T, Kaur G, Hession SL, Ganey PE, Roth RA. Synergistic Cytotoxicity from Drugs and Cytokines In Vitro as an Approach to Classify Drugs According to Their Potential to Cause Idiosyncratic Hepatotoxicity: A Proof-of-Concept Study. J Pharmacol Exp Ther 2017;362:459-73. [PMID: 28687704 DOI: 10.1124/jpet.117.242354] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
13 Lee SC, Arya V, Yang X, Volpe DA, Zhang L. Evaluation of transporters in drug development: Current status and contemporary issues. Adv Drug Deliv Rev 2017;116:100-18. [PMID: 28760687 DOI: 10.1016/j.addr.2017.07.020] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 7.8] [Reference Citation Analysis]
14 Bell SM, Chang X, Wambaugh JF, Allen DG, Bartels M, Brouwer KLR, Casey WM, Choksi N, Ferguson SS, Fraczkiewicz G, Jarabek AM, Ke A, Lumen A, Lynn SG, Paini A, Price PS, Ring C, Simon TW, Sipes NS, Sprankle CS, Strickland J, Troutman J, Wetmore BA, Kleinstreuer NC. In vitro to in vivo extrapolation for high throughput prioritization and decision making. Toxicol In Vitro 2018;47:213-27. [PMID: 29203341 DOI: 10.1016/j.tiv.2017.11.016] [Cited by in Crossref: 84] [Cited by in F6Publishing: 75] [Article Influence: 16.8] [Reference Citation Analysis]
15 Del Amo EM, Rimpelä AK, Heikkinen E, Kari OK, Ramsay E, Lajunen T, Schmitt M, Pelkonen L, Bhattacharya M, Richardson D, Subrizi A, Turunen T, Reinisalo M, Itkonen J, Toropainen E, Casteleijn M, Kidron H, Antopolsky M, Vellonen KS, Ruponen M, Urtti A. Pharmacokinetic aspects of retinal drug delivery. Prog Retin Eye Res 2017;57:134-85. [PMID: 28028001 DOI: 10.1016/j.preteyeres.2016.12.001] [Cited by in Crossref: 236] [Cited by in F6Publishing: 210] [Article Influence: 39.3] [Reference Citation Analysis]
16 Kenny JR, Ramsden D, Buckley DB, Dallas S, Fung C, Mohutsky M, Einolf HJ, Chen L, Dekeyser JG, Fitzgerald M, Goosen TC, Siu YA, Walsky RL, Zhang G, Tweedie D, Hariparsad N. Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidances from Regulatory Agencies: Focus on CYP3A4 mRNA In Vitro Response Thresholds, Variability, and Clinical Relevance. Drug Metab Dispos 2018;46:1285-303. [PMID: 29959133 DOI: 10.1124/dmd.118.081927] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
17 Tsamandouras N, Dickinson G, Guo Y, Hall S, Rostami-Hodjegan A, Galetin A, Aarons L. Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach. Pharm Res 2015;32:1864-83. [PMID: 25446771 DOI: 10.1007/s11095-014-1581-2] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
18 Pelkonen L, Sato K, Reinisalo M, Kidron H, Tachikawa M, Watanabe M, Uchida Y, Urtti A, Terasaki T. LC–MS/MS Based Quantitation of ABC and SLC Transporter Proteins in Plasma Membranes of Cultured Primary Human Retinal Pigment Epithelium Cells and Immortalized ARPE19 Cell Line. Mol Pharmaceutics 2017;14:605-13. [DOI: 10.1021/acs.molpharmaceut.6b00782] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
19 Yang K, Pfeifer ND, Hardwick RN, Yue W, Stewart PW, Brouwer KL. An experimental approach to evaluate the impact of impaired transport function on hepatobiliary drug disposition using Mrp2-deficient TR- rat sandwich-cultured hepatocytes in combination with Bcrp knockdown. Mol Pharm 2014;11:766-75. [PMID: 24410402 DOI: 10.1021/mp400471e] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
20 Fong SYK, Zuo Z. Species difference in the inhibitory potentials of non-steroidal anti-inflammatory drugs on the hepatic sulfation and glucuronidation of bioactive flavonoids: differential observations among common inhibition parameters. Xenobiotica 2013;44:417-31. [DOI: 10.3109/00498254.2013.851431] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
21 Barnett S, Ogungbenro K, Ménochet K, Shen H, Lai Y, Humphreys WG, Galetin A. Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B-Mediated Drug-Drug Interactions Using Population Pharmacokinetic Modeling and Simulation. Clin Pharmacol Ther 2018;104:564-74. [PMID: 29243231 DOI: 10.1002/cpt.983] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis]
22 Li N, Badrinarayanan A, Ishida K, Li X, Roberts J, Wang S, Hayashi M, Gupta A. Albumin-Mediated Uptake Improves Human Clearance Prediction for Hepatic Uptake Transporter Substrates Aiding a Mechanistic In Vitro-In Vivo Extrapolation (IVIVE) Strategy in Discovery Research. AAPS J 2021;23. [DOI: 10.1208/s12248-020-00528-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
23 Mohamed M, El Sheikh AK, Mohammed HH. Modulation of Liver P-Glycoprotien Expression May Contribute to Gossypin Protection against Methotrexate-Induced Hepatotoxicity. Indian J Pharmacol 2021;53:25-30. [PMID: 33975996 DOI: 10.4103/ijp.IJP_824_19] [Reference Citation Analysis]
24 Kenna JG, Taskar KS, Battista C, Bourdet DL, Brouwer KLR, Brouwer KR, Dai D, Funk C, Hafey MJ, Lai Y, Maher J, Pak YA, Pedersen JM, Polli JW, Rodrigues AD, Watkins PB, Yang K, Yucha RW; International Transporter Consortium. Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective. Clin Pharmacol Ther 2018;104:916-32. [PMID: 30137645 DOI: 10.1002/cpt.1222] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 12.3] [Reference Citation Analysis]
25 Terakosolphan W, Altharawi A, Poonprasartporn A, Harvey RD, Forbes B, Chan KLA. In vitro Fourier transform infrared spectroscopic study of the effect of glycerol on the uptake of beclomethasone dipropionate in living respiratory cells. Int J Pharm 2021;609:121118. [PMID: 34560211 DOI: 10.1016/j.ijpharm.2021.121118] [Reference Citation Analysis]
26 Riede J, Camenisch G, Huwyler J, Poller B. Current In Vitro Methods to Determine Hepatic Kp uu : A Comparison of Their Usefulness and Limitations. Journal of Pharmaceutical Sciences 2017;106:2805-14. [DOI: 10.1016/j.xphs.2017.03.025] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
27 Galetin A. Rationalizing underprediction of drug clearance from enzyme and transporter kinetic data: from in vitro tools to mechanistic modeling. Methods Mol Biol 2014;1113:255-88. [PMID: 24523117 DOI: 10.1007/978-1-62703-758-7_13] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
28 Ribeiro AJS, Yang X, Patel V, Madabushi R, Strauss DG. Liver Microphysiological Systems for Predicting and Evaluating Drug Effects. Clin Pharmacol Ther 2019;106:139-47. [PMID: 30993668 DOI: 10.1002/cpt.1458] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
29 Han TH, Zhao B. Absorption, distribution, metabolism, and excretion considerations for the development of antibody-drug conjugates. Drug Metab Dispos 2014;42:1914-20. [PMID: 25048520 DOI: 10.1124/dmd.114.058586] [Cited by in Crossref: 59] [Cited by in F6Publishing: 45] [Article Influence: 7.4] [Reference Citation Analysis]
30 Keemink J, Augustijns P, Annaert P. Unbound Ritonavir Concentrations in Rat and Human Hepatocytes. Journal of Pharmaceutical Sciences 2015;104:2378-87. [DOI: 10.1002/jps.24477] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
31 Nichols JW, Ladd MA, Fitzsimmons PN. Measurement of kinetic parameters for biotransformation of polycyclic aromatic hydrocarbons by trout liver S9 fractions: Implications for bioaccumulation assessment. Appl In Vitro Toxicol 2018;4:365-78. [PMID: 31179352 DOI: 10.1089/aivt.2017.0005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
32 Kojic M, Milosevic M, Simic V, Koay EJ, Kojic N, Ziemys A, Ferrari M. Multiscale smeared finite element model for mass transport in biological tissue: From blood vessels to cells and cellular organelles. Comput Biol Med 2018;99:7-23. [PMID: 29807251 DOI: 10.1016/j.compbiomed.2018.05.022] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
33 Kikuchi R, Chiou WJ, Kasai MA, de Morais SM, Bow DA. No Inhibition of MATE1/2K-Mediated Renal Creatinine Secretion Predicted With Ritonavir or Cobicistat. Journal of Pharmaceutical Sciences 2019;108:3118-23. [DOI: 10.1016/j.xphs.2019.04.023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
34 Tod M, Goutelle S, Bleyzac N, Bourguignon L. A Generic Model for Quantitative Prediction of Interactions Mediated by Efflux Transporters and Cytochromes: Application to P-Glycoprotein and Cytochrome 3A4. Clin Pharmacokinet 2019;58:503-23. [DOI: 10.1007/s40262-018-0711-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
35 Liu X, Wright M, Hop CE. Rational use of plasma protein and tissue binding data in drug design. J Med Chem 2014;57:8238-48. [PMID: 25099658 DOI: 10.1021/jm5007935] [Cited by in Crossref: 97] [Cited by in F6Publishing: 90] [Article Influence: 12.1] [Reference Citation Analysis]
36 Zhuang X, Shen G, Xiao W, Tan Y, Lu C, Li H. Assessment of the Roles of P-glycoprotein and Cytochrome P450 in Triptolide-induced Liver Toxicity in Sandwich-Cultured Rat Hepatocyte Model. Drug Metab Dispos 2013;41:2158-65. [DOI: 10.1124/dmd.113.054056] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
37 Bender A, Cortés-Ciriano I. Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: Ways to make an impact, and why we are not there yet. Drug Discov Today 2021;26:511-24. [PMID: 33346134 DOI: 10.1016/j.drudis.2020.12.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
38 Bizerra PFV, Guimarães ARJS, Miranda CA, Constantin RP, Utsunomiya KS, Gilglioni EH, Constantin J, Ishii-Iwamoto EL, Maioli MA, Mingatto FE. Enhanced cytotoxicity of imidacloprid by biotransformation in isolated hepatocytes and perfused rat liver. Pestic Biochem Physiol 2020;164:183-90. [PMID: 32284125 DOI: 10.1016/j.pestbp.2020.01.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Nagar S, Tucker J, Weiskircher EA, Bhoopathy S, Hidalgo IJ, Korzekwa K. Compartmental models for apical efflux by P-glycoprotein--part 1: evaluation of model complexity. Pharm Res 2014;31:347-59. [PMID: 24019023 DOI: 10.1007/s11095-013-1164-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
40 Sodhi JK, Liu S, Benet LZ. Challenging the Relevance of Unbound Tissue-to-Blood Partition Coefficient (Kpuu) on Prediction of Drug-Drug Interactions. Pharm Res 2020;37:73. [PMID: 32215750 DOI: 10.1007/s11095-020-02797-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
41 Rowe C, Shaeri M, Large E, Cornforth T, Robinson A, Kostrzewski T, Sison-Young R, Goldring C, Park K, Hughes D. Perfused human hepatocyte microtissues identify reactive metabolite-forming and mitochondria-perturbing hepatotoxins. Toxicol In Vitro 2018;46:29-38. [PMID: 28919358 DOI: 10.1016/j.tiv.2017.09.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
42 Anand A, Mallick SP, Singh BN, Kumari S, Suman DK, Tripathi S, Singh D, Srivastava P. A Critical Aspect of Bioreactor Designing and Its Application for the Generation of Tissue Engineered Construct: Emphasis on Clinical Translation of Bioreactor. Biotechnol Bioproc E. [DOI: 10.1007/s12257-021-0128-8] [Reference Citation Analysis]
43 Fouquet G, Debuysscher V, Ouled-Haddou H, Eugenio MS, Demey B, Singh AR, Ossart C, Al Bagami M, Regimbeau JM, Nguyen-Khac E, Naassila M, Marcq I, Bouhlal H. Hepatocyte SLAMF3 reduced specifically the multidrugs resistance protein MRP-1 and increases HCC cells sensitization to anti-cancer drugs. Oncotarget 2016;7:32493-503. [PMID: 27081035 DOI: 10.18632/oncotarget.8679] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
44 Zhang Y, Yin Q, Yen J, Li J, Ying H, Wang H, Hua Y, Chaney EJ, Boppart SA, Cheng J. Non-invasive, real-time reporting drug release in vitro and in vivo. Chem Commun (Camb) 2015;51:6948-51. [PMID: 25798457 DOI: 10.1039/c4cc09920f] [Cited by in Crossref: 38] [Cited by in F6Publishing: 5] [Article Influence: 5.4] [Reference Citation Analysis]
45 Lee CA, O’connor MA, Ritchie TK, Galetin A, Cook JA, Ragueneau-majlessi I, Ellens H, Feng B, Taub ME, Paine MF, Polli JW, Ware JA, Zamek-gliszczynski MJ. Breast Cancer Resistance Protein (ABCG2) in Clinical Pharmacokinetics and Drug Interactions: Practical Recommendations for Clinical Victim and Perpetrator Drug-Drug Interaction Study Design. Drug Metab Dispos 2015;43:490-509. [DOI: 10.1124/dmd.114.062174] [Cited by in Crossref: 80] [Cited by in F6Publishing: 72] [Article Influence: 11.4] [Reference Citation Analysis]
46 Tron C, Lemaitre F, Verstuyft C, Petitcollin A, Verdier M, Bellissant E. Pharmacogenetics of Membrane Transporters of Tacrolimus in Solid Organ Transplantation. Clin Pharmacokinet 2019;58:593-613. [DOI: 10.1007/s40262-018-0717-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
47 Bergman A, Bi Y, Mathialagan S, Litchfield J, Kazierad DJ, Pfefferkorn JA, Varma MV. Effect of Hepatic Organic Anion‐Transporting Polypeptide 1B Inhibition and Chronic Kidney Disease on the Pharmacokinetics of a Liver‐Targeted Glucokinase Activator: A Model‐Based Evaluation. Clin Pharmacol Ther 2019;106:792-802. [DOI: 10.1002/cpt.1419] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
48 Lu WJ, Lin HJ, Hsu PH, Lin HV. Determination of Drug Efflux Pump Efficiency in Drug-Resistant Bacteria Using MALDI-TOF MS. Antibiotics (Basel) 2020;9:E639. [PMID: 32987695 DOI: 10.3390/antibiotics9100639] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Riede J, Poller B, Huwyler J, Camenisch G. Assessing the Risk of Drug-Induced Cholestasis Using Unbound Intrahepatic Concentrations. Drug Metab Dispos 2017;45:523-31. [DOI: 10.1124/dmd.116.074179] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
50 Atienzar FA, Blomme EA, Chen M, Hewitt P, Kenna JG, Labbe G, Moulin F, Pognan F, Roth AB, Suter-Dick L, Ukairo O, Weaver RJ, Will Y, Dambach DM. Key Challenges and Opportunities Associated with the Use of In Vitro Models to Detect Human DILI: Integrated Risk Assessment and Mitigation Plans. Biomed Res Int 2016;2016:9737920. [PMID: 27689095 DOI: 10.1155/2016/9737920] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 5.7] [Reference Citation Analysis]
51 Patilea-Vrana GI, Unadkat JD. When Does the Rate-Determining Step in the Hepatic Clearance of a Drug Switch from Sinusoidal Uptake to All Hepatobiliary Clearances? Implications for Predicting Drug-Drug Interactions. Drug Metab Dispos 2018;46:1487-96. [PMID: 30115647 DOI: 10.1124/dmd.118.081307] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
52 Bonnaventure P, Cusin F, Pastor CM. Hepatocyte Concentrations of Imaging Compounds Associated with Transporter Inhibition: Evidence in Perfused Rat Livers. Drug Metab Dispos 2019;47:412-8. [PMID: 30674615 DOI: 10.1124/dmd.118.084624] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
53 Riley RJ, Foley SA, Barton P, Soars MG, Williamson B. Hepatic drug transporters: the journey so far. Expert Opin Drug Metab Toxicol. 2016;12:201-216. [PMID: 26670591 DOI: 10.1517/17425255.2016.1132308] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
54 Ufuk A, Assmus F, Francis L, Plumb J, Damian V, Gertz M, Houston JB, Galetin A. In Vitro and in Silico Tools To Assess Extent of Cellular Uptake and Lysosomal Sequestration of Respiratory Drugs in Human Alveolar Macrophages. Mol Pharm 2017;14:1033-46. [PMID: 28252969 DOI: 10.1021/acs.molpharmaceut.6b00908] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
55 Lee W, Koyama S, Morita K, Kiriake A, Kikuchi R, Chu X, Lee N, Scialis RJ, Shen H, Kimoto E, Tremaine L, Ishiguro N, Lotz R, Maeda K, Kusuhara H, Sugiyama Y. Cell-to-Medium Concentration Ratio Overshoot in the Uptake of Statins by Human Hepatocytes in Suspension, but Not in Monolayer: Kinetic Analysis Suggesting a Partial Loss of Functional OATP1Bs. AAPS J 2020;22:133. [PMID: 33063163 DOI: 10.1208/s12248-020-00512-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
56 Motohashi H, Inui K. Pharmacological and Toxicological Significance of the Organic Cation Transporters OCT and MATE: Drug Disposition, Interaction and Toxicity. In: Ciarimboli G, Gautron S, Schlatter E, editors. Organic Cation Transporters. Cham: Springer International Publishing; 2016. pp. 73-92. [DOI: 10.1007/978-3-319-23793-0_3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
57 Köck K, Ferslew BC, Netterberg I, Yang K, Urban TJ, Swaan PW, Stewart PW, Brouwer KL. Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4. Drug Metab Dispos. 2014;42:665-674. [PMID: 24154606 DOI: 10.1124/dmd.113.054304] [Cited by in Crossref: 108] [Cited by in F6Publishing: 96] [Article Influence: 12.0] [Reference Citation Analysis]
58 Smith DA, Rowland M. Intracellular and Intraorgan Concentrations of Small Molecule Drugs: Theory, Uncertainties in Infectious Diseases and Oncology, and Promise. Drug Metab Dispos 2019;47:665-72. [PMID: 30910784 DOI: 10.1124/dmd.118.085951] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
59 Amacher DE. The regulation of human hepatic drug transporter expression by activation of xenobiotic-sensing nuclear receptors. Expert Opin Drug Metab Toxicol 2016;12:1463-77. [PMID: 27548410 DOI: 10.1080/17425255.2016.1223626] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
60 Wissel G, Kudryavtsev P, Ghemtio L, Tammela P, Wipf P, Yliperttula M, Finel M, Urtti A, Kidron H, Xhaard H. Exploring the structure-activity relationships of ABCC2 modulators using a screening approach. Bioorg Med Chem 2015;23:3513-25. [PMID: 25935289 DOI: 10.1016/j.bmc.2015.04.029] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
61 Jiang P, Zhang X, Huang Y, Cheng N, Ma Y. Hepatotoxicity Induced by Sophora flavescens and Hepatic Accumulation of Kurarinone, a Major Hepatotoxic Constituent of Sophora flavescens in Rats. Molecules 2017;22:E1809. [PMID: 29068394 DOI: 10.3390/molecules22111809] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
62 Iwaki Y, Lee W, Sugiyama Y. Comparative and quantitative assessment on statin efficacy and safety: insights into inter-statin and inter-individual variability via dose- and exposure-response relationships. Expert Opin Drug Metab Toxicol 2019;15:897-911. [PMID: 31648563 DOI: 10.1080/17425255.2019.1681399] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
63 Zhang X, Wang R, Piotrowski M, Zhang H, Leach KL. Intracellular concentrations determine the cytotoxicity of adefovir, cidofovir and tenofovir. Toxicol In Vitro 2015;29:251-8. [PMID: 25448811 DOI: 10.1016/j.tiv.2014.10.019] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
64 Franchetti Y, Nolin TD. Simultaneous Assessment of Hepatic Transport and Metabolism Pathways with a Single Probe Using Individualized PBPK Modeling of 14CO2 Production Rate Data. J Pharmacol Exp Ther 2019;371:151-61. [PMID: 31399494 DOI: 10.1124/jpet.119.257212] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
65 Silva AM, Barbosa IA, Seabra C, Beltrão N, Santos R, Vega-Naredo I, Oliveira PJ, Cunha-Oliveira T. Involvement of mitochondrial dysfunction in nefazodone-induced hepatotoxicity. Food Chem Toxicol 2016;94:148-58. [PMID: 27288927 DOI: 10.1016/j.fct.2016.06.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
66 Templeton IE, Chen Y, Mao J, Lin J, Yu H, Peters S, Shebley M, Varma MV. Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help? CPT Pharmacometrics Syst Pharmacol 2016;5:505-15. [PMID: 27642087 DOI: 10.1002/psp4.12110] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
67 Guo Y, Chu X, Parrott NJ, Brouwer KLR, Hsu V, Nagar S, Matsson P, Sharma P, Snoeys J, Sugiyama Y, Tatosian D, Unadkat JD, Huang SM, Galetin A; International Transporter Consortium. Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches. Clin Pharmacol Ther 2018;104:865-89. [PMID: 30059145 DOI: 10.1002/cpt.1183] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 15.5] [Reference Citation Analysis]
68 . Phase 1-Phase 3 Clinical Studies, Procedures, Responsibilities, and Documentation. Translational ADMET for Drug Therapy. Hoboken: John Wiley & Sons, Inc; 2015. pp. 277-306. [DOI: 10.1002/9781118838440.ch10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
69 Kell DB, Oliver SG. How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion. Front Pharmacol 2014;5:231. [PMID: 25400580 DOI: 10.3389/fphar.2014.00231] [Cited by in Crossref: 93] [Cited by in F6Publishing: 89] [Article Influence: 11.6] [Reference Citation Analysis]
70 Harrison J, De Bruyn T, Darwich AS, Houston JB. Simultaneous Assessment In Vitro of Transporter and Metabolic Processes in Hepatic Drug Clearance: Use of a Media Loss Approach. Drug Metab Dispos 2018;46:405-14. [PMID: 29439129 DOI: 10.1124/dmd.117.079590] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
71 Daire J, Leporq B, Vilgrain V, Van Beers BE, Schmidt S, Pastor CM. Liver Perfusion Modifies Gd-DTPA and Gd-BOPTA Hepatocyte Concentrations Through Transfer Clearances Across Sinusoidal Membranes. Eur J Drug Metab Pharmacokinet 2017;42:657-67. [DOI: 10.1007/s13318-016-0382-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
72 Kojic M, Milosevic M, Simic V, Milicevic B, Geroski V, Nizzero S, Ziemys A, Filipovic N, Ferrari M. Smeared Multiscale Finite Element Models for Mass Transport and Electrophysiology Coupled to Muscle Mechanics. Front Bioeng Biotechnol 2019;7:381. [PMID: 31921800 DOI: 10.3389/fbioe.2019.00381] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
73 Yang K, Woodhead JL, Watkins PB, Howell BA, Brouwer KL. Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicity. Clin Pharmacol Ther 2014;96:589-98. [PMID: 25068506 DOI: 10.1038/clpt.2014.158] [Cited by in Crossref: 70] [Cited by in F6Publishing: 53] [Article Influence: 8.8] [Reference Citation Analysis]
74 Järvinen E, Kidron H, Finel M. Human efflux transport of testosterone, epitestosterone and other androgen glucuronides. The Journal of Steroid Biochemistry and Molecular Biology 2020;197:105518. [DOI: 10.1016/j.jsbmb.2019.105518] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
75 Baik J, Rosania GR. Modeling and Simulation of Intracellular Drug Transport and Disposition Pathways with Virtual Cell. J Pharm Pharmacol (Los Angel) 2013;1:1000004. [PMID: 24364041 DOI: 10.13188/2327-204X.1000004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
76 Fleming CL, Ashton TD, Nowell C, Devlin M, Natoli A, Schreuders J, Pfeffer FM. A fluorescent histone deacetylase (HDAC) inhibitor for cellular imaging. Chem Commun 2015;51:7827-30. [DOI: 10.1039/c5cc02059j] [Cited by in Crossref: 24] [Cited by in F6Publishing: 2] [Article Influence: 3.4] [Reference Citation Analysis]
77 Jang K, Chung H, Yoon J, Moon S, Yoon SH, Yu K, Kim K, Chung J. Pharmacokinetics, Safety, and Tolerability of Metformin in Healthy Elderly Subjects: Pharmacokinetics, Safety, and Tolerability of Metformin. The Journal of Clinical Pharmacology 2016;56:1104-10. [DOI: 10.1002/jcph.699] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
78 Pastor CM. How transfer rates generate Gd-BOPTA concentrations in rat liver compartments: implications for clinical liver imaging with hepatobiliary contrast agents: Generation of Gd-BOPTA hepatocyte concentrations. Contrast Media Mol Imaging 2016;11:291-8. [DOI: 10.1002/cmmi.1691] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
79 Yu J, Ritchie TK, Mulgaonkar A, Ragueneau-Majlessi I. Drug disposition and drug-drug interaction data in 2013 FDA new drug applications: a systematic review. Drug Metab Dispos. 2014;42:1991-2001. [PMID: 25271211 DOI: 10.1124/dmd.114.060392] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 4.5] [Reference Citation Analysis]
80 Korzekwa K, Nagar S. Compartmental models for apical efflux by P-glycoprotein: part 2--a theoretical study on transporter kinetic parameters. Pharm Res 2014;31:335-46. [PMID: 23959852 DOI: 10.1007/s11095-013-1163-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
81 Benet LZ, Bowman CM, Liu S, Sodhi JK. The Extended Clearance Concept Following Oral and Intravenous Dosing: Theory and Critical Analyses. Pharm Res 2018;35:242. [PMID: 30349948 DOI: 10.1007/s11095-018-2524-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
82 Stieger B, Hagenbuch B. Organic anion-transporting polypeptides. Curr Top Membr. 2014;73:205-232. [PMID: 24745984 DOI: 10.1016/b978-0-12-800223-0.00005-0] [Cited by in Crossref: 84] [Cited by in F6Publishing: 33] [Article Influence: 10.5] [Reference Citation Analysis]
83 Carusela MF, Miguel Rubi J. Computational Model for Membrane Transporters. Potential Implications for Cancer. Front Cell Dev Biol 2021;9:642665. [PMID: 33693005 DOI: 10.3389/fcell.2021.642665] [Reference Citation Analysis]
84 Scotcher D, Melillo N, Tadimalla S, Darwich AS, Ziemian S, Ogungbenro K, Schütz G, Sourbron S, Galetin A. Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats. Mol Pharm 2021;18:2997-3009. [PMID: 34283621 DOI: 10.1021/acs.molpharmaceut.1c00206] [Reference Citation Analysis]
85 Arruda AC, Perilhão MS, Santos WA, Gregnani MF, Budu A, Neto JCR, Estrela GR, Araujo RC. PPARα-Dependent Modulation by Metformin of the Expression of OCT-2 and MATE-1 in the Kidney of Mice. Molecules 2020;25:E392. [PMID: 31963528 DOI: 10.3390/molecules25020392] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
86 Rower JE, Jimmerson LC, Chen X, Zheng JH, Hodara A, Bushman LR, Anderson PL, Kiser JJ. Validation and Application of a Liquid Chromatography-Tandem Mass Spectrometry Method To Determine the Concentrations of Sofosbuvir Anabolites in Cells. Antimicrob Agents Chemother 2015;59:7671-9. [PMID: 26416874 DOI: 10.1128/AAC.01693-15] [Cited by in Crossref: 20] [Cited by in F6Publishing: 2] [Article Influence: 2.9] [Reference Citation Analysis]
87 Burtoloso AC, de Albuquerque S, Furber M, Gomes JC, Gonçalez C, Kenny PW, Leitão A, Montanari CA, Quilles JC Júnior, Ribeiro JF, Rocha JR. Anti-trypanosomal activity of non-peptidic nitrile-based cysteine protease inhibitors. PLoS Negl Trop Dis 2017;11:e0005343. [PMID: 28222138 DOI: 10.1371/journal.pntd.0005343] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
88 Modiwala M, Jadav T, Sahu AK, Tekade RK, Sengupta P. A Critical Review on Advancement in Analytical Strategies for the Quantification of Clinically Relevant Biological Transporters. Crit Rev Anal Chem 2021;:1-15. [PMID: 33691566 DOI: 10.1080/10408347.2021.1891859] [Reference Citation Analysis]
89 Harby SA, Nassra RA, Mekky JF, Ali SM, Ismail CA. Correlation of levetiracetam concentration in peripheral blood mononuclear cells with clinical efficacy: A sensitive monitoring biomarker in patients with epilepsy. Seizure 2020;78:71-7. [DOI: 10.1016/j.seizure.2020.03.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
90 Brouwer KLR, Keppler D, Hoffmaster KA, Bow DAJ, Cheng Y, Lai Y, Palm JE, Stieger B, Evers R. In Vitro Methods to Support Transporter Evaluation in Drug Discovery and Development. Clin Pharmacol Ther 2013;94:95-112. [DOI: 10.1038/clpt.2013.81] [Cited by in Crossref: 165] [Cited by in F6Publishing: 142] [Article Influence: 18.3] [Reference Citation Analysis]
91 Kulkarni P, Korzekwa K, Nagar S. A hybrid model to evaluate the impact of active uptake transport on hepatic distribution of atorvastatin in rats. Xenobiotica 2020;50:536-44. [PMID: 31530243 DOI: 10.1080/00498254.2019.1668982] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
92 Atilano-Roque A, Roda G, Fogueri U, Kiser JJ, Joy MS. Effect of Disease Pathologies on Transporter Expression and Function. J Clin Pharmacol. 2016;56 Suppl 7:S205-S221. [PMID: 27385176 DOI: 10.1002/jcph.768] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
93 Varma MV, El-kattan AF. Transporter-Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models. The Journal of Clinical Pharmacology 2016;56:S99-S109. [DOI: 10.1002/jcph.695] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
94 Iwasaki S, Hirabayashi H, Funami M, Amano N. Unbound liver concentration is the true inhibitor concentration that determines cytochrome P450-mediated drug–drug interactions in rat liver. Xenobiotica 2017;47:488-97. [DOI: 10.1080/00498254.2016.1204485] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
95 Marchitti SA, Mazur CS, Dillingham CM, Rawat S, Sharma A, Zastre J, Kenneke JF. Inhibition of the Human ABC Efflux Transporters P-gp and BCRP by the BDE-47 Hydroxylated Metabolite 6-OH-BDE-47: Considerations for Human Exposure. Toxicol Sci 2017;155:270-82. [PMID: 28031414 DOI: 10.1093/toxsci/kfw209] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
96 Kenna JG, Stahl SH, Eakins JA, Foster AJ, Andersson LC, Bergare J, Billger M, Elebring M, Elmore CS, Thompson RA. Multiple compound-related adverse properties contribute to liver injury caused by endothelin receptor antagonists. J Pharmacol Exp Ther. 2015;352:281-290. [PMID: 25467130 DOI: 10.1124/jpet.114.220491] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
97 Treyer A, Walday S, Boriss H, Matsson P, Artursson P. A Cell-Free Approach Based on Phospholipid Characterization for Determination of the Cell Specific Unbound Drug Fraction (fu,cell). Pharm Res 2019;36:178. [PMID: 31701258 DOI: 10.1007/s11095-019-2717-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
98 Scotcher D, Jones C, Posada M, Galetin A, Rostami-Hodjegan A. Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part II: Mechanistic Models and In Vitro-In Vivo Extrapolation. AAPS J 2016;18:1082-94. [PMID: 27506526 DOI: 10.1208/s12248-016-9959-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
99 Yoshikado T, Toshimoto K, Nakada T, Ikejiri K, Kusuhara H, Maeda K, Sugiyama Y. Comparison of Methods for Estimating Unbound Intracellular-to-Medium Concentration Ratios in Rat and Human Hepatocytes Using Statins. Drug Metab Dispos 2017;45:779-89. [DOI: 10.1124/dmd.116.074823] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
100 Yuan Z, Leung EL, Fan X, Zhou H, Ma W, Liu L, Xie Y. Quantitative evaluation of berberine subcellular distribution and cellular accumulation in non-small cell lung cancer cells by UPLC–MS/MS. Talanta 2015;144:20-8. [DOI: 10.1016/j.talanta.2015.05.017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
101 Atwa SM, Odenthal M, M El Tayebi H. Genetic Heterogeneity, Therapeutic Hurdle Confronting Sorafenib and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4343. [PMID: 34503153 DOI: 10.3390/cancers13174343] [Reference Citation Analysis]
102 Mateus A, Treyer A, Wegler C, Karlgren M, Matsson P, Artursson P. Intracellular drug bioavailability: a new predictor of system dependent drug disposition. Sci Rep 2017;7:43047. [PMID: 28225057 DOI: 10.1038/srep43047] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 8.8] [Reference Citation Analysis]
103 Galetin A, Zhao P, Huang SM. Physiologically Based Pharmacokinetic Modeling of Drug Transporters to Facilitate Individualized Dose Prediction. J Pharm Sci 2017;106:2204-8. [PMID: 28390843 DOI: 10.1016/j.xphs.2017.03.036] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
104 Tweedie D, Polli JW, Berglund EG, Huang SM, Zhang L, Poirier A, Chu X, Feng B; International Transporter Consortium. Transporter studies in drug development: experience to date and follow-up on decision trees from the International Transporter Consortium. Clin Pharmacol Ther. 2013;94:113-125. [PMID: 23588318 DOI: 10.1038/clpt.2013.77] [Cited by in Crossref: 96] [Cited by in F6Publishing: 91] [Article Influence: 10.7] [Reference Citation Analysis]
105 Wagner DJ, Hu T, Wang J. Polyspecific organic cation transporters and their impact on drug intracellular levels and pharmacodynamics. Pharmacol Res 2016;111:237-46. [PMID: 27317943 DOI: 10.1016/j.phrs.2016.06.002] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 9.2] [Reference Citation Analysis]
106 Kulkarni P, Korzekwa K, Nagar S. Intracellular Unbound Atorvastatin Concentrations in the Presence of Metabolism and Transport. J Pharmacol Exp Ther 2016;359:26-36. [PMID: 27451408 DOI: 10.1124/jpet.116.235689] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
107 Gao W, Webber AL, Maxwell J, Anderson M, Caro L, Chung C, Miltenburg AMM, Popa S, Van Dyck K, Wenning L, Mangin E, Fandozzi C, Railkar R, Shire NJ, Fraser I, Howell B, Talal AH, Stoch SA. Fine-Needle Aspiration for the Evaluation of Hepatic Pharmacokinetics of Vaniprevir: A Randomized Trial in Patients With Hepatitis C Virus Infection. Clin Pharmacol Ther 2020;107:1325-33. [PMID: 31868916 DOI: 10.1002/cpt.1737] [Reference Citation Analysis]
108 Broniarek I, Jarmuszkiewicz W. Atorvastatin affects negatively respiratory function of isolated endothelial mitochondria. Arch Biochem Biophys 2018;637:64-72. [PMID: 29217137 DOI: 10.1016/j.abb.2017.12.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
109 Williamson B, Riley RJ. Hepatic transporter drug-drug interactions: an evaluation of approaches and methodologies. Expert Opin Drug Metab Toxicol 2017;13:1237-50. [PMID: 29121476 DOI: 10.1080/17425255.2017.1404028] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
110 Lees P, Toutain PL, Elliott J, Giraudel JM, Pelligand L, King JN. Pharmacology, safety, efficacy and clinical uses of the COX-2 inhibitor robenacoxib. J Vet Pharmacol Ther 2022. [PMID: 35460083 DOI: 10.1111/jvp.13052] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Sistare FD, Mattes WB, Lecluyse EL. The Promise of New Technologies to Reduce, Refine, or Replace Animal Use while Reducing Risks of Drug Induced Liver Injury in Pharmaceutical Development. ILAR J 2017;57:186-211. [DOI: 10.1093/ilar/ilw025] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 5.2] [Reference Citation Analysis]
112 Abbiati RA, Manca D. Enterohepatic Circulation Effect in Physiologically Based Pharmacokinetic Models: The Sorafenib Case. Ind Eng Chem Res 2017;56:3156-66. [DOI: 10.1021/acs.iecr.6b03686] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
113 Moore A, Chothe PP, Tsao H, Hariparsad N. Evaluation of the Interplay between Uptake Transport and CYP3A4 Induction in Micropatterned Cocultured Hepatocytes. Drug Metab Dispos 2016;44:1910-9. [PMID: 27655038 DOI: 10.1124/dmd.116.072660] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
114 Im H. Excretion and Clearance. In: Lee DS, editor. Radionanomedicine. Cham: Springer International Publishing; 2018. pp. 347-68. [DOI: 10.1007/978-3-319-67720-0_19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
115 Talal AH, Venuto CS, Younis I. Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment. Clin Pharmacol Drug Dev 2017;6:206-12. [PMID: 28263464 DOI: 10.1002/cpdd.336] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
116 Thakur A, Tan SPF, Chan JCY. Physiologically-Based Pharmacokinetic Modeling to Predict the Clinical Efficacy of the Coadministration of Lopinavir and Ritonavir against SARS-CoV-2. Clin Pharmacol Ther 2020;108:1176-84. [PMID: 32767755 DOI: 10.1002/cpt.2014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
117 Pfeifer ND, Harris KB, Yan GZ, Brouwer KL. Determination of intracellular unbound concentrations and subcellular localization of drugs in rat sandwich-cultured hepatocytes compared with liver tissue. Drug Metab Dispos 2013;41:1949-56. [PMID: 23990525 DOI: 10.1124/dmd.113.052134] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
118 Morse BL, MacGuire JG, Marino AM, Zhao Y, Fox M, Zhang Y, Shen H, Griffith Humphreys W, Marathe P, Lai Y. Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Clearance and Liver Partitioning of OATP and OCT Substrates in Cynomolgus Monkeys. AAPS J 2017;19:1878-89. [PMID: 29019117 DOI: 10.1208/s12248-017-0151-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
119 Govindarajan R, Sparreboom A. Drug Transporters: Advances and Opportunities. Clin Pharmacol Ther 2016;100:398-403. [PMID: 27718234 DOI: 10.1002/cpt.454] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
120 Hernández Lozano I, Karch R, Bauer M, Blaickner M, Matsuda A, Wulkersdorfer B, Hacker M, Zeitlinger M, Langer O. Towards Improved Pharmacokinetic Models for the Analysis of Transporter-Mediated Hepatic Disposition of Drug Molecules with Positron Emission Tomography. AAPS J 2019;21:61. [PMID: 31037511 DOI: 10.1208/s12248-019-0323-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
121 Battista C, Yang K, Stahl SH, Mettetal JT, Watkins PB, Siler SQ, Howell BA. Using Quantitative Systems Toxicology to Investigate Observed Species Differences in CKA-Mediated Hepatotoxicity. Toxicol Sci 2018;166:123-30. [PMID: 30060248 DOI: 10.1093/toxsci/kfy191] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
122 Watkins J, Klaassen C. Absorption, Enterohepatic Circulation, and Fecal Excretion of Toxicants. Comprehensive Toxicology. Elsevier; 2018. pp. 99-112. [DOI: 10.1016/b978-0-12-801238-3.02122-x] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
123 Rizk ML, Zou L, Savic RM, Dooley KE. Importance of Drug Pharmacokinetics at the Site of Action. Clin Transl Sci 2017;10:133-42. [PMID: 28160433 DOI: 10.1111/cts.12448] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 10.0] [Reference Citation Analysis]
124 Nicolaï J, De Bruyn T, Van Veldhoven PP, Keemink J, Augustijns P, Annaert P. Verapamil hepatic clearance in four preclinical rat models: towards activity-based scaling. Biopharm Drug Dispos 2015;36:462-80. [PMID: 25963583 DOI: 10.1002/bdd.1959] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
125 Morse BL, Cai H, Macguire JG, Fox M, Zhang L, Zhang Y, Gu X, Shen H, Dierks EA, Su H, Luk CE, Marathe P, Shu Y, Humphreys WG, Lai Y. Rosuvastatin Liver Partitioning in Cynomolgus Monkeys: Measurement In Vivo and Prediction Using In Vitro Monkey Hepatocyte Uptake. Drug Metab Dispos 2015;43:1788-94. [DOI: 10.1124/dmd.115.065946] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
126 Karageorgis A, Lenhard SC, Yerby B, Forsgren MF, Liachenko S, Johansson E, Pilling MA, Peterson RA, Yang X, Williams DP, Ungersma SE, Morgan RE, Brouwer KLR, Jucker BM, Hockings PD. A multi-center preclinical study of gadoxetate DCE-MRI in rats as a biomarker of drug induced inhibition of liver transporter function. PLoS One 2018;13:e0197213. [PMID: 29771932 DOI: 10.1371/journal.pone.0197213] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
127 Namisaki T, Schaeffeler E, Fukui H, Yoshiji H, Nakajima Y, Fritz P, Schwab M, Nies AT. Differential expression of drug uptake and efflux transporters in Japanese patients with hepatocellular carcinoma. Drug Metab Dispos. 2014;42:2033-2040. [PMID: 25231932 DOI: 10.1124/dmd.114.059832] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
128 Kenna JG. Current Concepts in Drug-Induced Bile Salt Export Pump (BSEP) Interference. Curr Protoc Toxicol 2014;61:23.7.1-15. [PMID: 25104267 DOI: 10.1002/0471140856.tx2307s61] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
129 Matsunaga N, Ufuk A, Morse BL, Bedwell DW, Bao J, Mohutsky MA, Hillgren KM, Hall SD, Houston JB, Galetin A. Hepatic Organic Anion Transporting Polypeptide-Mediated Clearance in the Beagle Dog: Assessing In Vitro-In Vivo Relationships and Applying Cross-Species Empirical Scaling Factors to Improve Prediction of Human Clearance. Drug Metab Dispos 2019;47:215-26. [PMID: 30593544 DOI: 10.1124/dmd.118.084194] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
130 Min KA, Zhang X, Yu JY, Rosania GR. Computational approaches to analyse and predict small molecule transport and distribution at cellular and subcellular levels. Biopharm Drug Dispos 2014;35:15-32. [PMID: 24218242 DOI: 10.1002/bdd.1879] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
131 Keemink J, Wuyts B, Nicolaï J, Jonghe SD, Stella A, Herdewijn P, Augustijns P, Annaert P. In vitro disposition profiling of heterocyclic compounds. International Journal of Pharmaceutics 2015;491:78-90. [DOI: 10.1016/j.ijpharm.2015.05.080] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
132 Ramsden D, Tweedie DJ, Chan TS, Taub ME, Li Y. Bridging In Vitro and In Vivo Metabolism and Transport of Faldaprevir in Human Using a Novel Cocultured Human Hepatocyte System, HepatoPac. Drug Metab Dispos 2014;42:394-406. [DOI: 10.1124/dmd.113.055897] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 6.1] [Reference Citation Analysis]
133 Ufuk A, Somers G, Houston JB, Galetin A. In Vitro Assessment of Uptake and Lysosomal Sequestration of Respiratory Drugs in Alveolar Macrophage Cell Line NR8383. Pharm Res 2015;32:3937-51. [PMID: 26224396 DOI: 10.1007/s11095-015-1753-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
134 Tipping WJ, Lee M, Brunton VG, Lloyd-Jones GC, Hulme AN. Kinetic analysis of bioorthogonal reaction mechanisms using Raman microscopy. Faraday Discuss 2019;220:71-85. [PMID: 31531436 DOI: 10.1039/c9fd00057g] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
135 Johnson EJ, Won CS, Köck K, Paine MF. Prioritizing pharmacokinetic drug interaction precipitants in natural products: application to OATP inhibitors in grapefruit juice. Biopharm Drug Dispos 2017;38:251-9. [PMID: 28032362 DOI: 10.1002/bdd.2061] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
136 Fan Y, Sun B, Agarwal S, Zhang L. Review of Transporter-Related Postmarketing Requirement or Postmarketing Commitment Studies. The Journal of Clinical Pharmacology 2016;56:S193-204. [DOI: 10.1002/jcph.770] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
137 Pastor CM, Müllhaupt B, Stieger B. The Role of Organic Anion Transporters in Diagnosing Liver Diseases by Magnetic Resonance Imaging. Drug Metab Dispos 2014;42:675-84. [DOI: 10.1124/dmd.113.055707] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
138 Wulkersdorfer B, Wanek T, Bauer M, Zeitlinger M, Müller M, Langer O. Using positron emission tomography to study transporter-mediated drug-drug interactions in tissues. Clin Pharmacol Ther 2014;96:206-13. [PMID: 24682030 DOI: 10.1038/clpt.2014.70] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
139 Wright DH, Caro L, Cerra M, Panorchan P, Du L, Anderson M, Potthoff A, Nachbar RB, Wagner J, Manns MP, Talal AH. Liver-to-plasma vaniprevir (MK-7009) concentration ratios in HCV-infected patients. Antivir Ther 2015;20:843-8. [PMID: 25849338 DOI: 10.3851/IMP2958] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
140 Polak S, Tylutki Z, Holbrook M, Wiśniowska B. Better prediction of the local concentration-effect relationship: the role of physiologically based pharmacokinetics and quantitative systems pharmacology and toxicology in the evolution of model-informed drug discovery and development. Drug Discov Today 2019;24:1344-54. [PMID: 31132414 DOI: 10.1016/j.drudis.2019.05.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
141 Mann A, Semenenko I, Meir M, Eyal S. Molecular Imaging of Membrane Transporters' Activity in Cancer: a Picture is Worth a Thousand Tubes. AAPS J 2015;17:788-801. [PMID: 25823669 DOI: 10.1208/s12248-015-9752-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
142 Li R, Barton HA, Varma MV. Prediction of Pharmacokinetics and Drug–Drug Interactions When Hepatic Transporters are Involved. Clin Pharmacokinet 2014;53:659-78. [DOI: 10.1007/s40262-014-0156-z] [Cited by in Crossref: 74] [Cited by in F6Publishing: 67] [Article Influence: 9.3] [Reference Citation Analysis]
143 O'Connor M, Lee C, Ellens H, Bentz J. A novel application of t-statistics to objectively assess the quality of IC50 fits for P-glycoprotein and other transporters. Pharmacol Res Perspect 2015;3:e00078. [PMID: 25692007 DOI: 10.1002/prp2.78] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
144 Nagaraj A, Wilson SA, Vaidyanathan L. Anti-Obesity Properties of Calocybe Indica in Zebra fishes with Short-Term High-Fat Diet Induction. Biomed Pharmacol J 2021;14:411-23. [DOI: 10.13005/bpj/2141] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
145 Okudaira N. Evaluation of New Chemical Entities as Substrates of Liver Transporters in the Pharmaceutical Industry: Response to Regulatory Requirements and Future Steps. J Pharm Sci 2017;106:2251-6. [PMID: 28533120 DOI: 10.1016/j.xphs.2017.05.009] [Reference Citation Analysis]
146 Chu X, Prasad B, Neuhoff S, Yoshida K, Leeder JS, Mukherjee D, Taskar K, Varma MVS, Zhang X, Yang X, Galetin A. Clinical Implications of Altered Drug Transporter Abundance/Function and PBPK Modeling in Specific Populations: An ITC Perspective. Clin Pharmacol Ther 2022. [PMID: 35561140 DOI: 10.1002/cpt.2643] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
147 Bertarello A, Berruyer P, Artelsmair M, Elmore CS, Heydarkhan-Hagvall S, Schade M, Chiarparin E, Schantz S, Emsley L. In-Cell Quantification of Drugs by Magic-Angle Spinning Dynamic Nuclear Polarization NMR. J Am Chem Soc 2022. [PMID: 35385274 DOI: 10.1021/jacs.1c12442] [Reference Citation Analysis]
148 Schuetz JD, Swaan PW, Tweedie DJ. The role of transporters in toxicity and disease. Drug Metab Dispos 2014;42:541-5. [PMID: 24598705 DOI: 10.1124/dmd.114.057539] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
149 De Bruyn T, Ufuk A, Cantrill C, Kosa RE, Bi Y, Niosi M, Modi S, Rodrigues AD, Tremaine LM, Varma MVS, Galetin A, Houston JB. Predicting Human Clearance of Organic Anion Transporting Polypeptide Substrates Using Cynomolgus Monkey: In Vitro–In Vivo Scaling of Hepatic Uptake Clearance. Drug Metab Dispos 2018;46:989-1000. [DOI: 10.1124/dmd.118.081315] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
150 Ramsden D, Tweedie DJ, St. George R, Chen L, Li Y. Generating an In Vitro–In Vivo Correlation for Metabolism and Liver Enrichment of a Hepatitis C Virus Drug, Faldaprevir, Using a Rat Hepatocyte Model (HepatoPac). Drug Metab Dispos 2014;42:407-14. [DOI: 10.1124/dmd.113.055947] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
151 Chu X, Bleasby K, Chan GH, Nunes I, Evers R. The Complexities of Interpreting Reversible Elevated Serum Creatinine Levels in Drug Development: Does a Correlation with Inhibition of Renal Transporters Exist? Drug Metab Dispos 2016;44:1498-509. [PMID: 26825641 DOI: 10.1124/dmd.115.067694] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 8.8] [Reference Citation Analysis]
152 Gore E, Bigaeva E, Oldenburger A, Kim YO, Rippmann JF, Schuppan D, Boersema M, Olinga P. PI3K inhibition reduces murine and human liver fibrogenesis in precision-cut liver slices. Biochem Pharmacol 2019;169:113633. [PMID: 31494146 DOI: 10.1016/j.bcp.2019.113633] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
153 Korzekwa K. Case Study 4. Predicting the Drug Interaction Potential for Inhibition of CYP2C8 by Montelukast. In: Nagar S, Argikar UA, Tweedie DJ, editors. Enzyme Kinetics in Drug Metabolism. Totowa: Humana Press; 2014. pp. 461-9. [DOI: 10.1007/978-1-62703-758-7_21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
154 Chu X, Shih SJ, Shaw R, Hentze H, Chan GH, Owens K, Wang S, Cai X, Newton D, Castro-Perez J, Salituro G, Palamanda J, Fernandis A, Ng CK, Liaw A, Savage MJ, Evers R. Evaluation of cynomolgus monkeys for the identification of endogenous biomarkers for hepatic transporter inhibition and as a translatable model to predict pharmacokinetic interactions with statins in humans. Drug Metab Dispos 2015;43:851-63. [PMID: 25813937 DOI: 10.1124/dmd.115.063347] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 6.9] [Reference Citation Analysis]
155 Wu Y, Liu L, Zhao Y, Zhao R. Polysaccharides of vinegar-baked radix bupleuri promote the hepatic targeting effect of oxymatrine by regulating the protein expression of HNF4α, Mrp2, and OCT1. J Ethnopharmacol 2021;267:113471. [PMID: 33075440 DOI: 10.1016/j.jep.2020.113471] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
156 Yadav J, El Hassani M, Sodhi J, Lauschke VM, Hartman JH, Russell LE. Recent developments in in vitro and in vivo models for improved translation of preclinical pharmacokinetics and pharmacodynamics data. Drug Metab Rev 2021;53:207-33. [PMID: 33989099 DOI: 10.1080/03602532.2021.1922435] [Reference Citation Analysis]
157 Liu H, Sahi J. Role of Hepatic Drug Transporters in Drug Development. The Journal of Clinical Pharmacology 2016;56:S11-22. [DOI: 10.1002/jcph.703] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
158 Ferslew BC, Johnston CK, Tsakalozou E, Bridges AS, Paine MF, Jia W, Stewart PW, Barritt AS 4th, Brouwer KL. Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis. Clin Pharmacol Ther 2015;97:419-27. [PMID: 25669174 DOI: 10.1002/cpt.66] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 6.9] [Reference Citation Analysis]
159 Zhang J, Wu J, Li H, Chen Q, Lin J. An in vitro liver model on microfluidic device for analysis of capecitabine metabolite using mass spectrometer as detector. Biosensors and Bioelectronics 2015;68:322-8. [DOI: 10.1016/j.bios.2015.01.013] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 6.4] [Reference Citation Analysis]
160 Nguyen HQ, Lin J, Kimoto E, Callegari E, Tse S, Obach RS. Prediction of Losartan-Active Carboxylic Acid Metabolite Exposure Following Losartan Administration Using Static and Physiologically Based Pharmacokinetic Models. Journal of Pharmaceutical Sciences 2017;106:2758-70. [DOI: 10.1016/j.xphs.2017.03.032] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
161 Venuto CS, Markatou M, Woolwine-Cunningham Y, Furlage R, Ocque AJ, DiFrancesco R, Dumas EO, Wallace PK, Morse GD, Talal AH. Paritaprevir and Ritonavir Liver Concentrations in Rats as Assessed by Different Liver Sampling Techniques. Antimicrob Agents Chemother 2017;61:e02283-16. [PMID: 28264852 DOI: 10.1128/AAC.02283-16] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
162 Noorlander A, Fabian E, van Ravenzwaay B, Rietjens IMCM. Novel testing strategy for prediction of rat biliary excretion of intravenously administered estradiol-17β glucuronide. Arch Toxicol 2021;95:91-102. [PMID: 33159584 DOI: 10.1007/s00204-020-02908-x] [Reference Citation Analysis]
163 Nishiyama K, Toshimoto K, Lee W, Ishiguro N, Bister B, Sugiyama Y. Physiologically-Based Pharmacokinetic Modeling Analysis for Quantitative Prediction of Renal Transporter-Mediated Interactions Between Metformin and Cimetidine. CPT Pharmacometrics Syst Pharmacol 2019;8:396-406. [PMID: 30821133 DOI: 10.1002/psp4.12398] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
164 Chien HC, Zur AA, Maurer TS, Yee SW, Tolsma J, Jasper P, Scott DO, Giacomini KM. Rapid Method To Determine Intracellular Drug Concentrations in Cellular Uptake Assays: Application to Metformin in Organic Cation Transporter 1-Transfected Human Embryonic Kidney 293 Cells. Drug Metab Dispos 2016;44:356-64. [PMID: 26700958 DOI: 10.1124/dmd.115.066647] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 5.9] [Reference Citation Analysis]
165 Chu X, Liao M, Shen H, Yoshida K, Zur AA, Arya V, Galetin A, Giacomini KM, Hanna I, Kusuhara H, Lai Y, Rodrigues D, Sugiyama Y, Zamek-gliszczynski MJ, Zhang L; on behalf of the International Transporter Consortium. Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium. Clin Pharmacol Ther 2018;104:836-64. [DOI: 10.1002/cpt.1216] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 14.3] [Reference Citation Analysis]
166 Zamek-gliszczynski MJ, Chu X, Polli JW, Paine MF, Galetin A. Understanding the Transport Properties of Metabolites: Case Studies and Considerations for Drug Development. Drug Metab Dispos 2014;42:650-64. [DOI: 10.1124/dmd.113.055558] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
167 Venuto CS, Talal AH. Intrahepatic Sampling for the Elucidation of Antiviral Clinical Pharmacology. Clin Pharmacol Drug Dev 2017;6:169-75. [PMID: 28263459 DOI: 10.1002/cpdd.311] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
168 Sastry J, Mohammed H, Campos MM, Uetrecht J, Abu-Asab M. Nevirapine-induced liver lipid-SER inclusions and other ultrastructural aberrations. Ultrastruct Pathol 2018;42:108-15. [PMID: 29424579 DOI: 10.1080/01913123.2017.1422831] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]